ACM
BNTC icon

Altium Capital Management’s Benitec Biopharma BNTC Stock Holding History

Altium Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,753
Closed -$245K – 103
2022
Q3 		$245K Buy
+38,753
New +$492K 0.09% 101

Other funds holding BNTC

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Altium Capital Management's BNTC Position: Q4 2022 in Review

Altium Capital Management sold out of Benitec Biopharma (BNTC) in Q4 2022, closing a stake of 38,753 shares — an estimated $245K sold.

Altium Capital Management first reported a position in BNTC in Q3 2022 and held it in 1 quarter. The position peaked at $245K in Q3 2022. 25 funds tracked by Wall St. Rank hold BNTC as of Q4 2022.

  • Altium Capital Management reported no remaining Benitec Biopharma position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 38,753 Benitec Biopharma shares in Q4 2022, an estimated $245K.
  • Altium Capital Management first reported a position in Benitec Biopharma in Q3 2022 and held it in 1 quarter.
  • Altium Capital Management's Benitec Biopharma position peaked at $245K in Q3 2022.
  • 25 funds tracked by Wall St. Rank held Benitec Biopharma as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.